[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

RU93054168A - DIMER OF THE MOLECULAR OPTION OF ARO-LIPOPROTEIN, METHOD OF ITS PRODUCTION, PHARMACEUTICAL COMPOSITION ON ITS BASIS - Google Patents

DIMER OF THE MOLECULAR OPTION OF ARO-LIPOPROTEIN, METHOD OF ITS PRODUCTION, PHARMACEUTICAL COMPOSITION ON ITS BASIS

Info

Publication number
RU93054168A
RU93054168A RU93054168/14A RU93054168A RU93054168A RU 93054168 A RU93054168 A RU 93054168A RU 93054168/14 A RU93054168/14 A RU 93054168/14A RU 93054168 A RU93054168 A RU 93054168A RU 93054168 A RU93054168 A RU 93054168A
Authority
RU
Russia
Prior art keywords
dimer
apo
lipoprotein
aro
option
Prior art date
Application number
RU93054168/14A
Other languages
Russian (ru)
Other versions
RU2134696C1 (en
Inventor
Чиртори Чезаре
Франческини Гвидо
Абрамсен Ларс
Холмгрен Эрик
Лаке Матс
Нильссон Бъерн
Кмиелевска Йоанна
Линд Петер
Original Assignee
Каби Фармациа АБ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9103701A external-priority patent/SE9103701D0/en
Application filed by Каби Фармациа АБ filed Critical Каби Фармациа АБ
Publication of RU93054168A publication Critical patent/RU93054168A/en
Application granted granted Critical
Publication of RU2134696C1 publication Critical patent/RU2134696C1/en

Links

Claims (1)

Предлагаемое изобретение относится к чистым димерам аро-липопротеина Al-Milano/Apo AI-M/Apo AI-M/, которые сначала были выделены из плазмы и охарактеризованы. Оно также относится к фармацевтическим составам, включающим Apo AI-M/Apo AI-M. Димер аро-липопротеина AI-M был получен в системе рекомбинантной Escherichia coli или выделен из плазмы носителей аро-липопротеина AI-Milano. Настоящее изобретение также включает способ лечения атеросклероза и сердечно-сосудистых заболеваний и использование димера в приготовлении лекарств. Лекарства, содержащие димер, могут быть использованы для лечения атеросклероза и сердечно-сосудистых заболеваний, а также для предотвращения тромбозов в различных клинических обстоятельствах как на артериальном, так и на венозном уровне. Димер также может действовать как про-лекарство для мономера.The present invention relates to pure Al-Milano / Apo AI-M / Apo AI-M / apo-lipoprotein dimers, which were first isolated from plasma and characterized. It also relates to pharmaceutical formulations comprising Apo AI-M / Apo AI-M. The AI-M aro-lipoprotein dimer was obtained in the recombinant Escherichia coli system or isolated from the plasma of AI-Milano apo-lipoprotein carriers. The present invention also includes a method of treating atherosclerosis and cardiovascular disease, and the use of a dimer in the preparation of drugs. Dimer-containing drugs can be used to treat atherosclerosis and cardiovascular diseases, as well as to prevent thrombosis in various clinical circumstances, both at the arterial and venous levels. A dimer may also act as a pro-drug for the monomer.
RU93054168A 1991-12-13 1992-12-11 Dimer of molecular variant of apo-lipoprotein, method of its preparing and pharmaceutical composition on said RU2134696C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9103701A SE9103701D0 (en) 1991-12-13 1991-12-13 apolipoprotein
SE9103701-0 1991-12-13
PCT/SE1992/000858 WO1993012143A1 (en) 1991-12-13 1992-12-11 Dimer of molecular variant of apolipoprotein and processes for the production thereof

Publications (2)

Publication Number Publication Date
RU93054168A true RU93054168A (en) 1996-10-10
RU2134696C1 RU2134696C1 (en) 1999-08-20

Family

ID=20384608

Family Applications (1)

Application Number Title Priority Date Filing Date
RU93054168A RU2134696C1 (en) 1991-12-13 1992-12-11 Dimer of molecular variant of apo-lipoprotein, method of its preparing and pharmaceutical composition on said

Country Status (28)

Country Link
US (2) US5876968A (en)
EP (1) EP0571602B1 (en)
JP (1) JPH07502892A (en)
AT (1) ATE242269T1 (en)
AU (2) AU3175593A (en)
BG (1) BG61451B1 (en)
BR (1) BR9205640A (en)
CA (1) CA2103996C (en)
CZ (1) CZ289879B6 (en)
DE (1) DE69233092T2 (en)
DK (1) DK0571602T3 (en)
EE (1) EE03058B1 (en)
ES (1) ES2199939T3 (en)
FI (1) FI115771B (en)
HU (2) HU217203B (en)
IL (1) IL103956A (en)
MX (1) MX9207224A (en)
NO (1) NO315076B1 (en)
NZ (2) NZ280516A (en)
PL (3) PL172544B1 (en)
PT (1) PT571602E (en)
RO (1) RO115636B1 (en)
RU (1) RU2134696C1 (en)
SE (1) SE9103701D0 (en)
SG (1) SG47453A1 (en)
SK (1) SK86893A3 (en)
WO (1) WO1993012143A1 (en)
ZA (1) ZA928989B (en)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9103701D0 (en) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab apolipoprotein
SE9203753D0 (en) * 1992-12-11 1992-12-11 Kabi Pharmacia Ab EXPRESSION SYSTEM FOR PRODUCING APOLIPOPROTEIN AI-M
SE9500778D0 (en) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
FR2734568B1 (en) * 1995-05-22 1997-06-20 Rhone Poulenc Rorer Sa NEW VARIANTS OF APOLIPOPROTEIN
US6258596B1 (en) 1995-05-22 2001-07-10 Aventis Pharmaceuticals Products Inc. Variants of apolipoprotein A-I
SE9603068D0 (en) 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603304D0 (en) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a compound
SE9603303D0 (en) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
US6306433B1 (en) 1997-08-12 2001-10-23 Pharmacia Ab Method of preparing pharmaceutical compositions
US20020064820A1 (en) * 2000-03-13 2002-05-30 Jean-Michel Dayer Apo-A-I regulation of T-cell signaling
ES2260219T3 (en) * 2000-04-21 2006-11-01 Amgen Inc. APO-AI / AII PEPTID DERIVATIVES.
BRPI0003386B8 (en) * 2000-08-08 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda homo- or heterodimeric prodrugs useful in treating diseases or disorders mediated by phosphodiesterases; pharmaceutical compositions containing the prodrug or its pharmaceutical acceptable salts; process of obtaining these prodrugs
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
EP1335938B1 (en) 2000-11-10 2010-09-22 F. Hoffmann-La Roche Ltd. Apolipoprotein construct
US7217785B2 (en) * 2001-05-09 2007-05-15 The Regents Of The University Of California Cysteine-containing peptides having antioxidant properties
CN1943790A (en) 2001-09-28 2007-04-11 埃斯佩里安医疗公司 Prevention and treatment of restenosis by local administration of drug
CA2468989A1 (en) * 2001-12-07 2003-06-19 Daniel M. Schwartz Treatment for age-related macular degeneration
US20030229062A1 (en) * 2001-12-07 2003-12-11 The Regents Of The University Of California Treatments for age-related macular degeneration (AMD)
US7470659B2 (en) 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
US7223726B2 (en) * 2002-01-14 2007-05-29 The Regents Of The University Of California Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
US20100204103A1 (en) * 2002-05-08 2010-08-12 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
US20040038891A1 (en) * 2002-05-17 2004-02-26 Bisgaier Charles L. Methods and compositions for the treatment of ischemic reperfusion
CA2486127C (en) 2002-05-17 2014-03-11 Esperion Therapeutics, Inc. Method of treating dyslipidemic disorders
DE10324447A1 (en) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generation of artificial binding proteins based on ubiquitin
PE20050438A1 (en) * 2003-10-20 2005-06-14 Esperion Therapeutics Inc PHARMACEUTICAL FORMULAS, METHODS AND DOSING REGIMES FOR THE TREATMENT AND PREVENTION OF ACUTE CORONARY SYNDROMES
WO2005051413A2 (en) * 2003-11-26 2005-06-09 Novartis Ag Disease associated genes
WO2005058938A2 (en) * 2003-12-15 2005-06-30 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
WO2005097206A2 (en) * 2004-04-06 2005-10-20 Cedars-Sinai Medical Center Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein a-i and apolipoprotein a-i milano
KR100560102B1 (en) * 2004-06-25 2006-03-13 한국생명공학연구원 Prophylactic and therapeutic agents containing point mutants of proapolipoprotein A-I for anti-atherosclerosis and anti-hyperlipidemia
WO2012047930A2 (en) * 2010-10-04 2012-04-12 The Regents Of The University Of California Compositions and methods for treatment of gynecologic cancers
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
EP2368561B1 (en) 2005-04-29 2013-12-04 The Regents of The University of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
WO2007000924A1 (en) * 2005-06-28 2007-01-04 Osaka University Pharmaceutical composition comprising substance capable of inhibiting or promoting progranulin activity and screening method for substance capable of inhibiting or promoting progranulin activity
KR100719389B1 (en) 2005-10-18 2007-05-17 주식회사 녹십자 Method for manufacturing purified apolipoprotein A-I product from human plasma
US20070254832A1 (en) * 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
AU2007284801A1 (en) 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
US9637753B2 (en) * 2006-08-10 2017-05-02 Plantechno S.R.L. In-plant production of oligomeric (comprising three or more units) forms of human Apo A-1 protein muteins
US8541236B2 (en) * 2006-12-08 2013-09-24 University Of Washington Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls
WO2009032702A2 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
JP2010538005A (en) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション Synthetic apolipoprotein E mimetic polypeptides and methods of use
WO2009050266A2 (en) * 2007-10-19 2009-04-23 Pronota N.V. Use of n-terminal and c-terminal proteomics technology to enhance protein therapeutics and diagnostics
EP2212351B1 (en) 2007-10-23 2017-09-13 The Cleveland Clinic Foundation Oxidant resistant apolipoprotein a-1 and mimetic peptides
US8241861B1 (en) 2008-07-08 2012-08-14 Insilicos, Llc Methods and compositions for diagnosis or prognosis of cardiovascular disease
WO2010054405A1 (en) 2008-11-10 2010-05-14 Alnylam Pharmaceuticals, Inc. Novel lipids and compositions for the delivery of therapeutics
CA2751342C (en) 2009-01-29 2019-05-07 Alnylam Pharmaceuticals, Inc. Lipid formulations comprising cationic lipid and a targeting lipid comprising n-acetyl galactosamine for delivery of nucleic acid
JP6032724B2 (en) 2009-03-12 2016-11-30 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Lipid preparation composition and method for inhibiting expression of Eg5 gene and VEGF gene
CA3151387A1 (en) 2009-05-05 2010-11-11 Arbutus Biopharma Corporation Lipid compositions for the delivery of therapeutic agents
TR201811076T4 (en) 2009-06-10 2018-08-27 Arbutus Biopharma Corp Improved lipid formulation.
EP2464336A4 (en) 2009-08-14 2013-11-20 Alnylam Pharmaceuticals Inc Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
US10525152B2 (en) 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
WO2011071860A2 (en) 2009-12-07 2011-06-16 Alnylam Pharmaceuticals, Inc. Compositions for nucleic acid delivery
KR101436222B1 (en) * 2009-12-14 2014-09-01 쉴 프로테인즈 게엠베하 A method for identifying hetero-multimeric modified ubiquitin proteins with binding capability to ligands
US20130017223A1 (en) 2009-12-18 2013-01-17 The University Of British Columbia Methods and compositions for delivery of nucleic acids
US20130156845A1 (en) 2010-04-29 2013-06-20 Alnylam Pharmaceuticals, Inc. Lipid formulated single stranded rna
WO2011143362A1 (en) * 2010-05-11 2011-11-17 Esperion Therapeutics, Inc. Dimeric oxidation-resistant apolipoprotein a1 variants
CA2800401C (en) 2010-06-03 2020-09-15 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
US20130323269A1 (en) 2010-07-30 2013-12-05 Muthiah Manoharan Methods and compositions for delivery of active agents
WO2012016188A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012024309A2 (en) 2010-08-18 2012-02-23 Cedars-Sinai Medical Center Atherosclerosis inhibition via modulation of monocyte-macrophage phenotype using apo a-i milano gene transfer
US9339513B2 (en) 2010-11-09 2016-05-17 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
WO2012099755A1 (en) 2011-01-11 2012-07-26 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
DK2673296T3 (en) 2011-02-07 2019-02-18 Cerenis Therapeutics Holding Sa LIPOPROTEIN COMPLEXES AND PREPARATION AND APPLICATIONS THEREOF
EP2721152B1 (en) 2011-06-15 2019-03-27 Navigo Proteins GmbH Dimeric binding proteins based on modified ubiquitins
RU2014108240A (en) 2011-08-25 2015-09-27 Ф. Хоффманн-Ля Рош Аг SHORTED TETRANEKTIN-APOLIPOPROTEIN A-I HYBRID PROTEIN CONTAINING ITS LIPID PARTICLE AND THEIR APPLICATIONS
JP6250543B2 (en) 2011-09-27 2017-12-20 アルニラム・ファーマシューティカルズ・インコーポレーテッド Dialiphatic substituted PEGylated lipids
WO2014011908A1 (en) 2012-07-11 2014-01-16 Esperion Therapeutics, Inc. Apolipoprotein mixtures
EP2853259A1 (en) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
US20150316566A1 (en) 2014-05-02 2015-11-05 Cerenis Therapeutics Holding Sa Hdl therapy markers
AU2015298263B2 (en) 2014-07-31 2020-05-14 Anji Pharmaceuticals, Inc. ApoE mimetic peptides and higher potency to clear plasma cholesterol
US10858405B2 (en) 2015-02-06 2020-12-08 Navigo Proteins Gmbh EGFR binding proteins
BR112018000477A2 (en) 2015-07-16 2018-09-18 Navigo Proteins Gmbh unnatural immunoglobulin binding protein, composition, use of unnatural ig binding protein, immunoglobulin affinity purification method, method of generating an unnatural immunoglobulin binding protein, nucleic acid molecule, vector, host cell or a non-human host, and method for producing an unnatural immunoglobulin binding protein
US10584152B2 (en) 2015-07-20 2020-03-10 Navigo Proteins Gmbh Binding proteins based on di-ubiquitin muteins and methods for generation
AU2017260274A1 (en) 2016-05-04 2018-11-01 Navigo Proteins Gmbh Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
CA3031858A1 (en) 2016-08-11 2018-02-15 Repligen Corporation Alkaline stable fc-binding proteins for affinity chromatography
ES2984285T3 (en) 2017-08-10 2024-10-29 Abionyx Pharma Sa Cargomers
ES2984286T3 (en) 2017-08-10 2024-10-29 Abionyx Pharma Sa Apomers
WO2019091918A1 (en) 2017-11-07 2019-05-16 Navigo Proteins Gmbh Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer
JP2023522889A (en) 2020-04-16 2023-06-01 アビオニクス ファーマ エスエー Methods for treating acute conditions using lipid-binding protein-based conjugates
MX2023003877A (en) 2020-10-01 2023-04-18 Abionyx Pharma Sa Compositions comprising lipid binding protein-based complexes for use for treating eye diseases.
JP2024514154A (en) 2021-04-15 2024-03-28 アビオニクス ファーマ エスエー Use of lipid-binding protein-based complexes in organ preservation solutions
WO2023194798A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
WO2023194797A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
WO2023237935A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
WO2023237927A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
WO2024150064A1 (en) 2023-01-13 2024-07-18 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8625435D0 (en) * 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
IT1229996B (en) * 1989-04-20 1991-09-20 Cesare Sirtori EXPRESSION OF APOLIPOPROTEIN AI AND APOLIPOPROTEIN AI-MILAN IN YEAST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE APOLIPOPROTEINS.
SE9103701D0 (en) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab apolipoprotein

Similar Documents

Publication Publication Date Title
RU93054168A (en) DIMER OF THE MOLECULAR OPTION OF ARO-LIPOPROTEIN, METHOD OF ITS PRODUCTION, PHARMACEUTICAL COMPOSITION ON ITS BASIS
CA2103996A1 (en) Dimer of molecular variant of apolipoprotein and processes for the production thereof
RU2001116077A (en) A method for the treatment of cerebral ischemia, as well as the use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischemia
ES2170104T3 (en) INHIBITORS OF THE PRODUCTION OF BETA-AMILOID PROTEINS.
EA200100524A1 (en) AMIDES OF ANTRANILIC ACID AND THEIR APPLICATION AS MEDICINES
FI101377B1 (en) Process for the preparation of N-alkylated 1,4-dihydropyridine compounds
BR9500436A (en) Products use of a g-csf use of a tnf protein ligand process for the treatment and / or prevention of septic shock
DE69309790D1 (en) Cyclopentane perhydrophenanthrene-17-beta (3-furyl) -3 derivatives and pharmaceutical preparations thereof, for the treatment of cardiovascular diseases
FI961634A (en) Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides
EA200401295A1 (en) STATIN THERAPY TO ENHANCE SUPPORT OF COGNITIVE FUNCTION
DK0538690T3 (en) Arylquinolyl-substituted 1,4-dihydropyridine-dicarboxylic acid derivatives, process for their preparation in drug use
ATE184287T1 (en) DERIVATIVES OF PEPTIDES THERAPEUTICALLY EFFECTIVE IN THE BLOOD CLOTTING CAScade, METHOD FOR THE PRODUCTION AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME
RU93005013A (en) 1-AMINOSPIRO [IZOHINOLIN-4 (1H) 3-PYRROLIDIN-1,2,3,5 '(2H) -TETRONS] AND THEIR ANALOGUES, METHOD OF THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITION
RU93000004A (en) SUBSTANCE FOR TREATMENT OF SUBCUTANEOUS FIBRASARCOMA AND METHOD FOR ITS OBTAINING
RU93008090A (en) METHOD OF TREATMENT OF DEEP FROZEN BRUSHES
RU93057110A (en) APPENDECTOMY METHOD
RU93021719A (en) METHOD OF TREATMENT OF THE RETINA
RU93015924A (en) METHOD OF TREATMENT OF TROPHIC ULCERS OF THE LOWER EXTREMITIES
RU92016559A (en) DIALCOXY-PYRIDINYLBENZIMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION, METHOD FOR INHIBITING OR TREATMENT, METHOD FOR PRODUCING THEM, USE AND INTERMEDIATE COMPOUNDS
RU96114084A (en) METHOD FOR TREATING ALLERGIC DISEASES
RU93052444A (en) MEDICINE BAN
RU93005154A (en) PROCESSES, PHARMACEUTICAL COMPOSITION SYSTEMS